SLNCF — Silence Therapeutics Income Statement
0.000.00%
- $906.79m
- $714.03m
- £25.38m
- 63
- 11
- 57
- 40
Annual income statement for Silence Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.244 | 5.48 | 12.4 | 17.5 | 25.4 |
Cost of Revenue | |||||
Gross Profit | — | 1.72 | 4.96 | 6.62 | 15.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 23 | 41.3 | 58.2 | 66.1 | 75 |
Operating Profit | -22.7 | -35.8 | -45.8 | -48.6 | -49.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.9 | -36 | -45.9 | -47.4 | -50.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.6 | -32.5 | -39.4 | -40.5 | -43.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -19.6 | -32.5 | -39.4 | -40.5 | -43.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.6 | -32.5 | -39.4 | -40.5 | -43.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.261 | -0.398 | -0.443 | -0.419 | -0.389 |